EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Real-World Survival Outcomes in Non–Small Cell Lung Cancer: The Impact of Genomic Testing and Targeted Therapies in a Latin American Middle-Income Country

Juan-Manuel Hernandez-Martinez iD, Alberto Guijosa iD, Diana Flores-Estrada, Graciela Cruz-Rico, Jenny Turcott iD, Norma Hernández-Pedro iD, Enrique Caballé-Perez iD, Andrés F Cardona iD, Oscar Arrieta iD

JCO Global Oncology · 2024

DOI: 10.1200/go-24-00338 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift JCO Global Oncology, 2024. Verfasst von Juan-Manuel Hernandez-Martinez und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio de Medicina Personalizada de la Unidad de Oncología Torácica, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Molecular Targeted Therapy. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 54 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Targeted therapies are indicated for patients with non–small cell lung cancer (NSCLC) and driver tumor mutations. However, real-world studies on the survival benefits of these agents are limited. This study aimed to evaluate the effect of targeted therapies matched to a genomic alteration on the survival of patients with NSCLC. METHODS This retrospective study included 446 patients with advanced NSCLC who underwent next-generation sequencing between 2016 and 2023 at the Instituto Nacional de Cancerología in Mexico. The primary outcomes were progression-free survival (PFS) and overall survival (OS). RESULTS For the entire cohort, the PFS and OS were 10.71 months (95% CI, 9.35 to 12.06) and 47.77 months (95% CI, 29.67 to 65.86). PFS was significantly longer in patients with actionable mutations treated with targeted therapies (19.41 months [95% CI, 14.27 to 24.55]; P < .001) than in patients without actionable mutations (6.4 months [95% CI, 4.4 to 8.4]) or not treated with targeted therapies (6.6 months [95% CI, 5.3 to 7.89]). Similarly, OS was significantly longer in patients with actionable mutations treated with targeted therapies (89.69 months [95% CI, 45.54 to 133.84]; P < .001) than in patients without actionable mutations (17.11 months [95% CI, 8.65 to 25.57]) or not treated with targeted therapies (22.3 months [95% CI, 12.48 to 32.1]). Survival gains were driven by significant improvements in PFS and OS in patients with EGFR and ALK mutations. CONCLUSION This real-world data analysis demonstrated that targeted therapies improve the survival of patients with NSCLC with actionable mutations, which supports a recommendation for widening access to broad-based genomic testing and targeted therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsMolecular Targeted TherapyHumansFemaleMaleRetrospective StudiesMiddle AgedAgedMexicoMutationAdultAged, 80 and overHigh-Throughput Nucleotide SequencingGenetic TestingProgression-Free SurvivalGenomicsLatin America

Autor:innen und Institutionen

  • Laboratorio de Medicina Personalizada de la Unidad de Oncología Torácica, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
  • Thoracic Oncology Unit, Department of Thoracic Oncology, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
  • CONAHCYT-Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
  • Direction of Research and Education, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Bogotá, Colombia.
  • Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia.
  • Molecular Oncology and Biology Systems Research Group (FOX-G/ONCOLGroup), Universidad El Bosque, Bogotá, Colombia.

ORCID-Profile: Juan-Manuel Hernandez-Martinez, Alberto Guijosa, Jenny Turcott, Norma Hernández-Pedro, Enrique Caballé-Perez, Andrés F Cardona, Oscar Arrieta

Zitieren

APA

Hernandez-Martinez, J. M., Guijosa, A., Flores-Estrada, D., Cruz-Rico, G., Turcott, J., Hernández-Pedro, N., Caballé-Perez, E., Cardona, A. F., & Arrieta, O. (2024). Real-World Survival Outcomes in Non–Small Cell Lung Cancer: The Impact of Genomic Testing and Targeted Therapies in a Latin American Middle-Income Country. JCO Global Oncology. https://doi.org/10.1200/go-24-00338

Vancouver

Hernandez-Martinez JM, Guijosa A, Flores-Estrada D, Cruz-Rico G, Turcott J, Hernández-Pedro N, et al. Real-World Survival Outcomes in Non–Small Cell Lung Cancer: The Impact of Genomic Testing and Targeted Therapies in a Latin American Middle-Income Country. JCO Global Oncology. 2024. doi:10.1200/go-24-00338

BibTeX
@article{HernandezMartinez2024,
  author = {Hernandez-Martinez, Juan-Manuel and Guijosa, Alberto and Flores-Estrada, Diana and Cruz-Rico, Graciela and Turcott, Jenny and Hernández-Pedro, Norma and Caballé-Perez, Enrique and Cardona, Andrés F and Arrieta, Oscar},
  title = {Real-World Survival Outcomes in Non–Small Cell Lung Cancer: The Impact of Genomic Testing and Targeted Therapies in a Latin American Middle-Income Country},
  journal = {JCO Global Oncology},
  year = {2024},
  doi = {10.1200/go-24-00338}
}
Kostenlos starten →